Amgen’s Easy “On-Body” Tepezza Shot Crushes Phase 3 — Viridian Stock Plunges
Viridian shares fell after Amgen’s new, easy Tepezza shot showed strong results for Thyroid Eye Disease.
/ 3 items
#VRDN↓
Viridian’s Elegrobart Data: Promising Proptosis Win, But Missing the Full Picture for Thyroid Eye Disease
Viridian highlights 54% proptosis response for Elegrobart in TED, but secondary endpoints like inflammation and diplopia showed limited gains.
Viridian Therapeutics Gets Double Buy Rating After Roche's Weak TED Results
Jefferies and Wedbush maintain Buy ratings on Viridian Therapeutics as Roche's thyroid eye disease drug shows weaker results than Viridian's veligrotug therapy.